Mohsen Hosseini

Mohsen Hosseini

Auto-generated profile, based on publicly available information

Mohsen Hosseini

Princess Margaret Cancer Centre, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JSJEAN EMMANUEL SARRY
JEAN EMMANUEL SARRY
MSMarie Sabatier
Marie Sabatier
ESEstelle Saland
Estelle Saland
GCGuillaume Cognet
Guillaume Cognet
NPNathalie Poupin
Nathalie Poupin
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry
Mutations in IDH induce epigenetic and transcriptional reprogramming, differentiation bias, and susceptibility to mitochondrial inhibitors in cancer cells. Here, we first show that cell lines, PDXs, and patients with acute myeloid leukemia (AML) harboring an IDH mutation displayed an enhanced mitochondrial oxidative metabolism. Along with an increase in TCA cycle intermediates, this AML-specific metabolic behavior mechanistically occurred through the increase in electron transport chain complex I activity, mitochondrial respiration, and methylation-driven CEBPα-induced fatty acid β-oxidation of IDH1 mutant cells. While IDH1 mutant inhibitor reduced 2-HG oncometabolite and CEBPα methylation, it failed to reverse FAO and OxPHOS. These mitochondrial activities were maintained through the inhibition of Akt and enhanced activation of peroxisome proliferator-activated receptor-γ coactivator-1 PGC1α upon IDH1 mutant inhibitor. Accordingly, OxPHOS inhibitors improved anti-AML efficacy of IDH mutant inhibitors in vivo. This work provides a scientific rationale for combinatory mitochondrial-targeted therapies to treat IDH mutant AML patients, especially those unresponsive to or relapsing from IDH mutant inhibitors.

1 April 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SDStephanie M. Dobson
Stephanie M. Dobson
LGLaura García-Prat
Laura García-Prat
RVRobert J. Vanner
Robert J. Vanner
JWJeffrey Wintersinger
Jeffrey Wintersinger
EWEsmé Waanders
Esmé Waanders
JDJohn E. Dick
John E. Dick
Disease recurrence causes significant mortality in B-progenitor acute lymphoblastic leukemia (B-ALL). Genomic analysis of matched diagnosis and relapse samples shows relapse often arising from minor diagnosis subclones. However, why therapy eradicates some subclones while others survive and progress to relapse remains obscure. Elucidation of mechanisms underlying these differing fates requires functional analysis of isolated subclones. Here, large-scale limiting dilution xenografting of diagnosis and relapse samples, combined with targeted sequencing, identified and isolated minor diagnosis subclones that initiate an evolutionary trajectory toward relapse [termed diagnosis Relapse Initiating clones (dRI)]. Compared with other diagnosis subclones, dRIs were drug-tolerant with distinct engraftment and metabolic properties. Transcriptionally, dRIs displayed enrichment for chromatin remodeling, mitochondrial metabolism, proteostasis programs, and an increase in stemness pathways. The isolation and characterization of dRI subclones reveals new avenues for eradicating dRI cells by targeting their distinct metabolic and transcriptional pathways before further evolution renders them fully therapy-resistant. Significance: Isolation and characterization of subclones from diagnosis samples of patients with B-ALL who relapsed showed that relapse-fated subclones had increased drug tolerance and distinct metabolic and survival transcriptional programs compared with other diagnosis subclones. This study provides strategies to identify and target clinically relevant subclones before further evolution toward relapse. See related article by E. Waanders et al.

15 October 2019 in Cancer Research
Verified
Journal Article
Closed access
MHMohsen Hosseini
Mohsen Hosseini
HRHamid-Reza REZVANI
Hamid-Reza REZVANI
NANesrine Aroua
Nesrine Aroua
CBClaudie Bosc
Claudie Bosc
TFThomas FARGE
Thomas FARGE
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry
Chemotherapies alter cellular redox balance and reactive oxygen species (ROS) content. Recent studies have reported that chemoresistant cells have an increased oxidative state in hematologic malignancies. In this study, we demonstrated that chemoresistant acute myeloid leukemia (AML) cells had a lower level of mitochondrial and cytosolic ROS in response to cytarabine (AraC) and overexpressed myeloperoxidase (MPO), a heme protein that converts hydrogen peroxide to hypochlorous acid (HOCl), compared with sensitive AML cells. High MPO-expressing AML cells were less sensitive to AraC in vitro and in vivo. They also produced higher levels of HOCl and exhibited an increased rate of mitochondrial oxygen consumption when compared with low MPO-expressing AML cells. Targeting MPO expression or enzyme activity sensitized AML cells to AraC treatment by triggering oxidative damage and sustaining oxidative stress, particularly in high MPO-expressing AML cells. This sensitization stemmed from mitochondrial superoxide accumulation, which impaired oxidative phosphorylation and cellular energetic balance, driving apoptotic death and selective eradication of chemoresistant AML cells in vitro and in vivo. Altogether, this study uncovers a noncanonical function of MPO enzyme in maintaining redox balance and mitochondrial energetic metabolism, therefore affecting downstream pathways involved in AML chemoresistance. Significance: These findings demonstrate the role of myeloperoxidase in the regulation of ROS levels and sensitivity of AML cells to cytarabine, an essential chemotherapeutic backbone in the therapy of AML.

4 May 2015 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
NAN. Ali
N. Ali
MHM. Hosseini
M. Hosseini
Seppo VainioSeppo Vainio
Seppo Vainio
ATA. Taïeb
A. Taïeb
MCM. Cario‐André
M. Cario‐André
HRHamid-Reza REZVANI
Hamid-Reza REZVANI

1 October 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
NANesrine Aroua
Nesrine Aroua
EBEmeline Boet
Emeline Boet
MGMargherita Ghisi
Margherita Ghisi
MNMarie-Laure Nicolau-Travers
Marie-Laure Nicolau-Travers
ESEstelle Saland
Estelle Saland
JSJean-Emmanuel Sarry
Jean-Emmanuel Sarry
Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine-resistant leukemic cells from both AML cell lines and patient samples in vivo and in vitro. CD39 cell-surface expression and activity is increased in patients with AML upon chemotherapy compared with diagnosis, and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinics. High CD39 activity promotes cytarabine resistance by enhancing mitochondrial activity and biogenesis through activation of a cAMP-mediated adaptive mitochondrial stress response. Finally, genetic and pharmacologic inhibition of CD39 ecto-ATPase activity blocks the mitochondrial reprogramming triggered by cytarabine treatment and markedly enhances its cytotoxicity in AML cells in vitro and in vivo. Together, these results reveal CD39 as a new residual disease marker and a promising therapeutic target to improve chemotherapy response in AML. Significance: Extracellular ATP and CD39–P2RY13–cAMP–OxPHOS axis are key regulators of cytarabine resistance, offering a new promising therapeutic strategy in AML. This article is highlighted in the In This Issue feature, p. 1426

16 April 2025 in Nature
Verified
Journal Article
Closed access
PDF file
MHMohsen Hosseini
Mohsen Hosseini
VVVeronique Voisin
Veronique Voisin
ACAli Chegini
Ali Chegini
AVAngelica Varesi
Angelica Varesi
SCSeverine Cathelin
Severine Cathelin
SCSteven M. Chan
Steven M. Chan